Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.85 - $26.62
Previous CloseN/A
Volume146.35K
Average Volume (3M)272.56K
Market Cap
$157.73M
Enterprise Value$387.03M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,848,740
10 Day Avg. Volume157,359
30 Day Avg. Volume272,559
Standard Deviation0.34
R-Squared0.08
Alpha-0.27
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.85
Forecast
1Y Price Target
$6.33Price Target Upside40.67% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
CollaborationsBioAge highlighted collaborations with Lilly ExploR&D on two therapeutic antibodies for novel metabolic aging targets.
Financial PositionBioAge has a strong cash position with a runway to 2029+, allowing for multiple proof-of-concept studies to be run in parallel.
NLRP3 ProgramBGE-102 is 10x more potent than the company’s previous lead preclinical candidate, offering potential for multiple indications such as obesity and neuroinflammatory diseases.
Bears Say
Azelaprag DevelopmentThe future development of azelaprag remains unclear until the company provides an update.
Discontinuation Of STRIDES TrialBioAge discontinued its Phase 2 STRIDES study for azelaprag in obesity due to transaminase elevations in patients.
Stock Rating DowngradeThe stock rating has been downgraded to underweight.
---
Ownership Overview
13.56% Insiders
4.42% Mutual Funds
47.14% Other Institutional Investors
32.19% Public Companies and Individual Investors
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $3.85 and its highest was $26.62 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $157.73M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 07, 2024. The company reported -$6.7 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$6.023.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,848,740 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$6.7 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went up 7.614%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
---
BioAge Labs, Inc. Stock Smart Score
Company Description
BioAge Labs, Inc.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period.
---
BIOA Stock 12 Month Forecast
Average Price Target
$6.33
▲(40.67% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering BIOA
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-36.95%
reiterated a sell rating 26 days ago
Copying Jeffrey Hung's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -36.95% per trade.
---